Patterns of incident genital human papillomavirus infection in women: A literature review and meta-analysis

Human papillomavirus (HPV) infection acquisition is a necessary step in the development of cervical cancer. No study has systematically quantified the rate of newly acquired HPV infections from the published literature and determined its relationship with age. We performed a systematic review and meta-analysis to describe incident HPV infections in women. Medline® and Thomson Reuters Web of Science via PubMed® databases were searched. A total of 46 of 5136 studies met inclusion criteria and contributed results. We conducted a meta-regression analysis of 13 studies, which reported incidence rate estimates on over 13 high-risk HPV types, to provide pooled stratum-specific incidence rates and rate ratios for key population and study characteristics among 8488 women. Studies with mean age < 30 years had relatively higher HPV incidence rates compared to studies with mean age ≥30 years: relative risk = 3.12; 95% CI: 1.41–6.93. HPV-16 was most frequently detected, followed by HPV-18: relative risk = 0.47; 95% CI: 0.33–0.67, and by HPV-58: relative risk = 0.45; 95% CI: 0.27–0.74. Younger age is a key predictor of genital HPV incidence in women. These data on the relative distribution of incident HPV infections will provide a baseline comparison for monitoring of changes in HPV incidence following the implementation of population-level HPV vaccination.

[1]  H. Zou,et al.  Positivity and incidence of human papillomavirus in women attending gynecological department of a major comprehensive hospital in Kunming, China 2012–2014 , 2016, Journal of medical virology.

[2]  A. Chatterjee The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon , 2014, Expert review of vaccines.

[3]  J. Berkhof,et al.  Prospective follow‐up of 2,065 young unscreened women to study human papillomavirus incidence and clearance , 2013, International journal of cancer.

[4]  Joelle M. Brown,et al.  High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects , 2013, Sexually Transmitted Infections.

[5]  A. Burke,et al.  Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. , 2012, Cancer research.

[6]  S. Hibbitts Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial , 2012, Journal of Family Planning and Reproductive Health Care.

[7]  P. Gravitt The known unknowns of HPV natural history. , 2011, The Journal of clinical investigation.

[8]  S. Grénman,et al.  Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study , 2011, BMC infectious diseases.

[9]  H. Trottier,et al.  Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. , 2010, Cancer research.

[10]  N. Surico,et al.  Role of HPV testing in the follow-up of women treated for cervical dysplasia , 2010, Archives of Gynecology and Obstetrics.

[11]  C. Wheeler,et al.  Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  E. Weiderpass,et al.  Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda , 2010, Infectious Agents and Cancer.

[13]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[14]  X. Castellsagué,et al.  HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. , 2009, Gynecologic oncology.

[15]  A. Saah,et al.  Prevalence and Incidence of HPV Genital Infection in Women , 2009, Sexually transmitted diseases.

[16]  S. Kjaer,et al.  Acquisition of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women , 2009, Sexually transmitted diseases.

[17]  N. Muñoz,et al.  Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.

[18]  M. I. Rosa,et al.  Persistence and clearance of human papillomavirus infection: a prospective cohort study. , 2008, American journal of obstetrics and gynecology.

[19]  Yurii B. Shvetsov,et al.  Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. , 2008, Cancer research.

[20]  Jennifer S. Smith,et al.  Age-specific prevalence of infection with human papillomavirus in females: a global review. , 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[21]  N. Kiviat,et al.  Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. , 2008, The Journal of infectious diseases.

[22]  F. Buonaguro,et al.  Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. , 2008, The Journal of general virology.

[23]  S. Gange,et al.  Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda , 2008, Cancer Epidemiology Biomarkers & Prevention.

[24]  H. Trottier,et al.  Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. , 2008, The Journal of infectious diseases.

[25]  S. Franceschi,et al.  Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study , 2008, BMC infectious diseases.

[26]  E. Dasbach,et al.  Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women , 2007, Infectious Agents and Cancer.

[27]  N. Muñoz,et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.

[28]  S. Wacholder,et al.  The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life , 2007, Sexually transmitted diseases.

[29]  E. Dasbach,et al.  Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives , 2007, Cancer Epidemiology Biomarkers & Prevention.

[30]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[31]  Xavier Castellsagué,et al.  Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.

[32]  L. Parker,et al.  Human papillomavirus infection and cervical intraepithelial neoplasia in a cohort of low-risk women. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[33]  D. Tate,et al.  Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study , 2006, BMJ : British Medical Journal.

[34]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[35]  V. Moreno,et al.  Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. , 2005, The Journal of infectious diseases.

[36]  S. Wacholder,et al.  A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[37]  A. Muñoz,et al.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.

[38]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[39]  C. Wheeler,et al.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.

[40]  M. J. Whitley,et al.  Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring , 2004, Journal of medical virology.

[41]  S. Syrjänen,et al.  Acquisition of High-Risk Human Papillomavirus Infections and Pap Smear Abnormalities among Women in the New Independent States of the Former Soviet Union , 2004, Journal of Clinical Microbiology.

[42]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[43]  M. Abrahamowicz,et al.  Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities , 2003, Sexually transmitted diseases.

[44]  Michal Abrahamowicz,et al.  The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  J. Kaczorowski,et al.  Incidence, clearance and predictors of human papillomavirus infection in women. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[46]  C. Woodman,et al.  Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.

[47]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[48]  R. Burk,et al.  Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. , 2002, The Journal of infectious diseases.

[49]  A. Giuliano,et al.  Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.

[50]  R. Greenblatt,et al.  The Impact of HIV Infection and Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts , 2002, Sexually transmitted diseases.

[51]  N. Kiviat,et al.  Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[52]  L. Young,et al.  High incidence of cervical human papillomavirus infection in women during their first sexual relationship , 2002, BJOG : an international journal of obstetrics and gynaecology.

[53]  T. Rohan,et al.  Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. , 2001, The Journal of infectious diseases.

[54]  L. Ahdieh,et al.  Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. , 2001, The Journal of infectious diseases.

[55]  A. Moscicki,et al.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. , 2001, JAMA.

[56]  N. Kiviat,et al.  Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.

[57]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[58]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[59]  K. Shah,et al.  Detection of Genital Human Papillomavirus and Associated Cytological Abnormalities Among College Women , 1998, Sexually transmitted diseases.

[60]  S. Thompson,et al.  Detecting and describing heterogeneity in meta-analysis. , 1998, Statistics in medicine.

[61]  R. Burk,et al.  Natural history of cervicovaginal papillomavirus infection in young women , 1998 .

[62]  M. Chiasson,et al.  Human papillomavirus infection in women infected with the human immunodeficiency virus. , 1997, The New England journal of medicine.

[63]  J. Kónya,et al.  Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women Received: 17 July 1996 , 1996, Medical Microbiology and Immunology.

[64]  M. Evander,et al.  Human Papillomavirus Infection Is Transient in Young Women: A PopulationBased Cohort Study , 1995 .

[65]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[66]  H. Kitchener,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[67]  R. Pandey,et al.  Type-specific incidence and persistence of HPV infection among young women: a prospective study in North India. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[68]  Chee-Jen Chang,et al.  Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology—A population‐based cohort study from Taiwan , 2010, International journal of cancer.

[69]  J. T. Cox,et al.  American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2007, CA: a cancer journal for clinicians.

[70]  David R. Scott,et al.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.

[71]  M. Evander,et al.  Human papillomavirus infection is transient in young women: a population-based cohort study. , 1995, The Journal of infectious diseases.